ADMA Biologics, Inc. (NASDAQ:ADMA) has been identified as one of the Stocks That Could Mint Millionaires in 2026. The company specializes in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases both domestically and internationally.
One of the key products in ADMA’s portfolio is BIVIGAM, an intravenous immune globulin product used for the treatment of primary humoral immunodeficiency. Additionally, the company markets Nabi-HB, a human polyclonal antibody product designed for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. ADMA also has a pipeline of plasma-derived therapeutics in development.
In its recent earnings report for the third quarter of 2025, ADMA Biologics updated its revenue guidance for the full year. The company now expects total revenue for 2025 to reach $510 million, up from its previous guidance of over $500 million. Adjusted net income for 2025 was also revised to $158 million, reflecting a higher effective tax rate.
While ADMA Biologics presents a promising investment opportunity, there are other AI stocks in the market that offer even greater upside potential with less downside risk. Investors seeking undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend are encouraged to explore a free report on the best short-term AI stock.
For more investment insights, readers can check out 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for the Long Term. It’s essential to note that the author has no financial interest in ADMA Biologics, Inc. or any related securities mentioned in this article.
